KPRX
Kiora Pharmaceuticals, Inc.
There isn't enough reported data to score KPRX yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
KPRX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Strong |
KPRX's balance sheet is currently strong, but its profitability is weak. There isn't enough data to rate its revenue and cash flow.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
KPRX PE Valuation
KPRX has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
KPRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| -- | |
| -- | |
| Limited | |
| High |
Analysts expect KPRX's losses to shrink, with revenue holding steady.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
KPRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.79 | -$0.53 |
| Q2 2026 | -$2.50 | +$0.58 |
| Q1 2026 | -$2.70 | +$0.37 |
| Q4 2025 | -$2.64 | -403% |
| Q3 2022 | -$367.47 | +$183.33 |
| Q2 2022 | -$417.60 | +$187.20 |
| Q1 2022 | -$478.80 | +$136.80 |
| Q4 2021 | -$514.80 | +$122.40 |
KPRX lost $2.79 per share over the past year, a bigger loss than the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over KPRX on earnings quality, reporting a profit while its opponent remains loss making.
KPRX Quarterly Revenue
KPRX's revenue is growing: $1M last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -169% | N/A |
| Q2 2024 | -12724% | N/A |
| Q1 2024 | 83% | N/A |
LLY has the edge over KPRX on profitability, with a higher operating margin.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over KPRX on profitability, with a higher operating margin.
KPRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$557.9K | +$715.6K |
| Q1 2026 | -$3.2M | -$462.2K |
| Q4 2025 | -$2.3M | -$51.3K |
| Q3 2025 | -$1.3M | -238% |
| Q1 2025 | -$2.7M | -120% |
| Q4 2024 | -$2.2M | +$374K |
| Q3 2024 | $920.1K | +$3.4M |
| Q1 2024 | $13.6M | +$16.7M |
KPRX has burned cash in almost every quarter: −$8M over the past year, against −$5M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
KPRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.9% | +117K shares |
| 1 year | +44% | +1.9M shares |
| 3 years | +2940% | +6.1M shares |
| 5 years | +49822% | +6.3M shares |
KPRX has 6M diluted shares, up 44% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over KPRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
KPRX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2024 | -0.8x | Net Cash |
| Q3 2024 | -1.1x | Net Cash |
| Q2 2024 | -2.5x | Net Cash |
| Q1 2024 | -12.0x | Net Cash |
KPRX has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
KPRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 22.6 | Oversold |
| Stochastic | 1.2 | Oversold |
KPRX's weekly RSI is 23 (oversold) and its Stochastic is 1 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
KPRX PE vs Healthcare Sector
KPRX has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
KPRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.09 | 36% below |
| 20 week MA | $2.40 | 45% below |
| 50 week MA | $2.31 | 42% below |
| 100 week MA | $2.64 | 50% below |
| 200 week MA | $6.48 | 79% below |
KPRX is in a downtrend: it's below all five of its weekly moving averages, and 79% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over KPRX on trend strength, trading above more of its moving averages.
KPRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3,351.6 | $2,138.4 | -36% |
| 2021 | $2,138.4 | $312.5 | -85% |
| 2022 | $312.5 | $22.1 | -93% |
| 2023 | $22.1 | $4.70 | -79% |
| 2024 | $4.70 | $3.29 | -30% |
| 2025 | $3.29 | $1.97 | -40% |
| 2026 YTD | $1.97 | $1.33 | -32% |
KPRX has finished every year since 2020 lower, and it's down 32% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over KPRX on returns for 2026, with the stronger performance.